Royalty Pharma (FRA:RPD) Accounts Payable : €11 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Accounts Payable?

Royalty Pharma's Accounts Payable for the quarter that ended in Mar. 2024 was €11 Mil.

Royalty Pharma's quarterly Accounts Payable increased from Sep. 2023 (€13 Mil) to Dec. 2023 (€14 Mil) but then declined from Dec. 2023 (€14 Mil) to Mar. 2024 (€11 Mil).

Royalty Pharma's annual Accounts Payable increased from Dec. 2021 (€5 Mil) to Dec. 2022 (€7 Mil) and increased from Dec. 2022 (€7 Mil) to Dec. 2023 (€14 Mil).

Royalty Pharma Accounts Payable Historical Data

The historical data trend for Royalty Pharma's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Accounts Payable Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accounts Payable

Get a 7-Day Free Trial

10.06

8.86

4.97

7.46

13.91

Royalty Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable	Get a 7-Day Free Trial															6.22	5.36	12.77	13.91	10.63

Royalty Pharma Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Royalty Pharma Accounts Payable Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma (FRA:RPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (FRA:RPD) » Definitions » Accounts Payable

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPRX:Mexico RPD:Germany

Address

110 East 59th Street, FL 33, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.